Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.72 |
| ▸ | MEN1 | O00255 | 6/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10964661 | 0.88 | L3MBTL1 (0.77) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL11803436 | 0.88 | L3MBTL1 (0.71) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL10970617 | 0.87 | RAB9A (0.85) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL6272750 | 0.86 | HPGD (0.74) | KMT2AMEN1RAB9AALDH1A1GAA | |
| SCHEMBL5524698 | 0.86 | KMT2A (0.71) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL30716404 | 0.86 | KMT2A (0.71) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL5892567 | 0.86 | KMT2A (0.62) | KMT2AMEN1POLBRAB9AALDH1A1 | |
| SCHEMBL6580028 | 0.85 | L3MBTL1 (0.68) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL9030520 | 0.85 | L3MBTL1 (0.68) | L3MBTL1KMT2AMEN1POLBNR4A1 | |
| SCHEMBL7932304 | 0.84 | KMT2A (0.60) | L3MBTL1KMT2AMEN1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228579-A1 | METHOD FOR THE CATALYTIC REDUCTION OF ACID CHLORIDES AND IMIDOYL CHLORIDES | Brock Unviersity (CA) | 2014-08-14 | — | — | US | disclosed |
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-31 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | BECKWITH ROHAN | 2008-08-28 | — | — | US | disclosed |
| WO-2007025751-A1 | USE OF FUSED IMIDAZOLE DERIVATIVES TO MEDIATE CCR3 RELATED CONDITIONS | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| EP-0208846-B1 | [7-(3-Disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID CO (US) | 1993-11-18 | — | — | EP | disclosed |
| EP-0550576-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
| US-4626538-A | [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4521422-A | ANTICONVULSANT, ANTIEPILEPTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS | AMERICAN CYANAMID COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0129847-A2 | Aryl and heteroaryl[7-(aryl and heteroaryl)-pyrazolo-[1,5-a]-pyrimidin-3-yl]methanones | AMERICAN CYANAMID COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4014892-A | ANTHELMINTICS | AMERICAN CYANAMID COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-3989835-A | Method of using 6-substituted amino phenyl-2,3,5,6-tetra-hydro[2,1-b]thiazoles for controlling gastrointestinal nematodes | AMERICAN CYANAMID COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029967-A1 | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors | MTOR, PIK3CA, CDK2 | L3MBTL1 659/4885KMT2A 1289/4885MEN1 1180/4885 |
| US-20080207718-A1 | Use of Fused Imidazole Derivatives to Mediate Ccr3 Related Conditions | CCR3, CCR1, CCR4 | L3MBTL1 3206/4885KMT2A 3492/4885MEN1 3895/4885 |
| US-20140228579-A1 | METHOD FOR THE CATALYTIC REDUCTION OF ACID CHLORIDES AND IMIDOYL CHLORIDES | CA6, RUVBL2, HACL2 | L3MBTL1 1658/4885KMT2A 979/4885MEN1 3732/4885 |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | L3MBTL1 2530/4885KMT2A 2890/4885MEN1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.